medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2022, Number 2

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2022; 38 (2)

Association of peripheral blood lymphoid immunophenotype with presence of non-Hodgkin lymphomas

Suárez RA, Villegas VCA, Arango PMC, González MT, Gracia ME

Language: Spanish
References: 20
Page: 1-13
PDF size: 466.62 Kb.


ABSTRACT

Introduction: Lymphocyte immunophenotype changes in non-Hodgkin lymphoma patients are associated with prognosis and therapeutic responses. However, its association with the disease has not been systematically established. Therefor its contribution to the diagnosis process.
Objective: To assess the association of lymphocyte immunophenotype in peripheral blood with the presence of non-Hodgkin lymphoma.
Methods: 31 peripheral blood samples were analyzed from patients with a confirmed diagnosis of non-Hodgkin lymphoma and from 68 healthy individuals as controls, during the period 2018 to 2020. Multiparametric flow cytometry was used for immunophenotyping. The area under the curve and the Youden index were calculated to establish cut-off points in lymphocyte percentages. The association of immunophenotypic changes with non-Hodgkin's lymphoma was made using Odd ratio calculations.
Results: The increase in TCD8+ and NKCD56dim lymphocytes from peripheral blood was significantly associated with the presence of non-Hodgkin lymphoma (OR= 3.4 and 2.9, respectively). Oppositely, the decrease in TCD4+, double positive T, double negative T and NKCD56bright lymphocytes was associated with the existence of non-Hodgkin lymphoma (OR= 23.0, 10.7, 6.9 and 15.8, respectively). Therefore, the decrease in the CD4/CD8 rate was also associated with the disease.
Conclusion: The changes found in these lymphocytic immunophenotypes were significantly associated with the presence of non-Hodgkin lymphoma, which represents a systemic expression of the disease and suggests its diagnostic value.


REFERENCES

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. DOI: https://10.3322/caac.216601.

  2. MINSAP. Anuario estadístico de salud. La Habana 2021: MINSAP; 2021 [acceso 12/10/2021]; Disponible en: https://files.sld.cu/bvscuba/files/2021/08/Anuario-Estadistico-Español-2020-Definitivo.pdf2.

  3. Hus I, Staroslawska E, Bojarska-Junak A, Dobrzynska-Rutkowska A, Surdacka A, Wdowiak P, et al. CD3+/CD16+CD56+ cell numbers in peripheral blood are correlated with higher tumor burden in patients with diffuse large B-cell lymphoma. Folia Histochem Cytobiol. 2011;49(1):183-7. DOI: https://10.5603/fhc.2011.00253.

  4. Csizmar CM, Ansell SM. Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma. Int J Mol Sci. 2021;22(7):3302. DOI: https://10.3390/ijms220733024.

  5. Wu D, Thomas A, Fromm JR. Reactive T cells by flow cytometry distinguish Hodgkin lymphomas from T cell/histiocyte-rich large B cell lymphoma. Cytometry Part B: Clin Cytometry. 2016;90(5):424-32. DOI: https://10.1002/cyto.b.212615.

  6. Rahemtullah A, Reichard KK, Preffer FI, Harris NL, Hasserjian RP. A double-positive CD4+CD8+ T-cell population is commonly found in nodular lymphocyte predominant Hodgkin lymphoma. Am J Clin Pathol. 2006;126(5):805-14.

  7. Shin HJ, Kim DY, Chung JS, Shin KH, Lee H. Prognostic Impact of Peripheral Blood T-Cell Subsets at the Time of Diagnosis on Survival in Patients with Diffuse Large B-Cell Lymphoma. Acta Haematologica. 2021;144(4):427-37. DOI: https://10.1159/0005109127.

  8. Plonquet A, Haioun C, Jais JP, Debard AL, Salles G, Bene MC, et al. Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma. Ann Oncol. 2007;18(7):1209-15.

  9. De Tullio G, Minoia C, Serratì S, Merchionne F, Loseto G, La Pietra A, et al. The Functional Attitude and The Predictive Role Of An Unconventional Subset Of T Cells In Clinical Outcome Of Lymphoma Patients: aß-Double Negative T Cells, Preliminary Data Of a Prospective Study. Blood. 2013;122(21):4506.

  10. Hou H, Luo Y, Tang G, Zhang B, Ouyang R, Wang T, et al. Dynamic changes in peripheral blood lymphocyte subset counts and functions in patients with diffuse large B cell lymphoma during chemotherapy. Cancer Cell Int. 2021;21(1):282. DOI: https://10.1186/s12935-021-01978-w10.

  11. Garcia-Marquez MA, Thelen M, Reinke S, Keller D, Wennhold K, Lehmann J, et al. Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma. Leukemia. 2022;36(3):760-771. DOI: https://10.1038/s41375-021-01421-z11.

  12. Yang Z, Yu W, Wang S, Zhou X, Liu S, Ma S. Peripheral blood lymphocyte subsets of newly diagnosed DLBCL patients and their dynamic changes with rituximab based immunochemotherapy. Leuk Lymphoma. 2019;60(12):2909-16. DOI: https://10.1080/10428194.2019.161786112.

  13. Han X, Ruan J, Zhang W, Zhou D, Xu D, Pei Q, et al. Prognostic implication of leucocyte subpopulations in diffuse large B-cell lymphoma. Oncotarget. 2017;8(29):47790-800. DOI: https://10.18632/oncotarget.1783013.

  14. Lu Y, Yu J, Gong W, Su L, Sun X, Bai O, et al. An Immune-Clinical Prognostic Index (ICPI) for Patients With De Novo Follicular Lymphoma Treated With R-CHOP/CHOP Chemotherapy. Front Oncol. 2021;11:708784. DOI: https://10.3389/fonc.2021.70878414.

  15. Xia Y, Li W, Li Y, Liu Y, Ye S, Liu A, et al. The clinical value of the changes of peripheral lymphocyte subsets absolute counts in patients with non-small cell lung cancer. Transl Oncol. 2020;13(12):100849. DOI: https://10.1016/j.tranon.2020.10084915.

  16. Mu S, Ai L, Fan F, Qin Y, Sun C, Hu Y. Prognostic role of neutrophil-to-lymphocyte ratio in diffuse large B cell lymphoma patients: an updated dose-response meta-analysis. Cancer Cell Int. 2018;18:119. DOI: https://10.1186/s12935-018-0609-916.

  17. Zhang Y-P, Zhang R, Zhu H-Y, Wang L, Wu Y-J, Liang J-H, et al. Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy. Cancer Res Treat. 2019;51(1):368-77. DOI: https://10.4143/crt.2018.01017.

  18. Bruna R, Geuna M, Rota Scalabrini D, Cignetti A, Santoro N, Gottardi D, et al. Low Circulating B Lymphocytes in Newly Diagnosed Follicular and Diffuse Large B Cell Lymphoma: Differences Compared to Normal Subjects and Possible Prognostic Role. Blood. 2017;130(Suppl 1):1482. DOI: https://10.1182/blood.V130.Suppl_1.1482.148218.

  19. Amini RM, Enblad G, Hollander P, LaszloS, Eriksson E, Ayoola Gustafsson K, et al. Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients. BMC Cancer. 2019;19:316. DOI: https://10.1186/s12885-019-5529-019.

  20. Kusano Y, Yokoyama M, Terui Y, Nishimura N, Mishima Y, Ueda K, et al. Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma. Blood Cancer J. 2017;7:e558. DOI: https://10.1038/bcj.2017.3720.




2020     |     www.medigraphic.com